Vertex Pharmaceuticals Incorporated
http://www.vrtx.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Vertex Pharmaceuticals Incorporated
Argenx Eyes Hat-Trick Of Successful Launches For Vyvgart After CHMP Thumbs-Up
Anant Murthy, general manager of Argenx Europe, tells Scrip that the commercial infrastructure is in place for Vyvgart to enjoy a strong launch for the rare neuromuscular disorder which will mirror those seen in the US and Japan.
Novartis Dives Into In Vivo Gene-Editing With Precision Biosciences Deal
Novartis is once again looking to be a pioneer in cell and gene therapy, though this time is selecting a potentially less complex administration method.
Daiichi Eyes First-Line AML Filings For Vanflyta On Positive Data
Daiichi Sankyo is aiming to overcome past US and EU setbacks for its FLT3 inhibitor Vanflyta with planned filings for first-line AML on the back of positive new Phase III data.
BIO 2022 Notebook: Deal Values In The Eyes Of The Beholders
News and views from day 3 of the BIO annual meeting include business development insights, such as Sanofi's global head of BD Alban De La Sabliere's promise that big pharma has no hidden agenda and an AbbVie BD exec's observations that lower company valuations have not led to lower asking prices. Also, BIO chairman and Nkarta CEO Paul Hastings' optimism that biotech will rebound and Venus Williams' Sjogren's disease story draws a crowd.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Other Names / Subsidiaries
-
- ViroChem Pharma Inc., Exonics Therapeutics, Inc., Semma Therapeutics